Journal
INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE
Volume 27, Issue 6, Pages 511-515Publisher
WILEY
DOI: 10.1016/j.ijdevneu.2009.07.001
Keywords
QR2 physiology; MT3; Melatonin; Luzindole; Retina; Neurodevelopment
Categories
Funding
- CNPq [420013103-2]
Ask authors/readers for more resources
Luzindole is an unselective antagonist of the melatonin receptors and melatonin's other binding sites, although some exceptions have been observed in chick retinal neurodevelopment, where this unselective antagonist does not block melatonin's inhibitory effect on the adenylate cyclase enzyme, probably due to the presence of some other melatonin receptor(s) or binding site(s). The present study investigated the modulation of cyclic adenosine 3'-5'-monophosphate (cAMP) levels via MT3 melatoninbinding sites, located within the QR2 (dihydronicotinamide riboside: quinone oxidoreductase 2) enzyme, by observing the response to luzindole. Embryonic and post-hatch retinas, incubated with a selective agonist for the MT3 melatonin-binding site 5-methoxycarbonylamino-N-acetyltryptamine (5-MCA-NAT, 10 or 100 nM), had an increase in cAMP accumulation relative to control retinas. Luzindole (5 mu M) inhibited the 5-MCA-NAT stimulatory effect at all ages tested. The agonist 5-MCA-NAT enhanced the melatonin inhibitory effect on cAMP levels stimulated by forskolin (5 mu M), but not the stimulatory forskolin effect. The results suggest that MT3 melatonin-binding sites are present in embryonic and post-hatch chick retinas and that luzindole more selectively blocks the 5-MCA-NAT effect on cAMP accumulation than it blocks the melatonin inhibitory effect via G protein-coupled receptors in chick retinal neurodevelopment. (C) 2009 ISDN. Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available